Search
Search Results
##search.searchResults.foundPlural##
-
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2057PDF: 843HTML: 259 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1571PDF: 1042HTML: 237 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2199PDF: 974HTML: 2172 -
MANAGEMENT OF PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS
828PDF: 542HTML: 4026 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3737PDF: 1466HTML: 186 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7654PDF: 2437HTML: 1740Table 1.: 214Table 2.: 224Table 3.: 208Table 4.: 208 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3402PDF: 1292HTML: 2230Fi.1 Gritti.Rambaldi: 209 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1992PDF: 728HTML: 688Table1: patient's characteristics: 160Table 2: profile of each patient: 183 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2570PDF: 1158HTML: 144 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
837PDF: 483Suppl. Files: 125HTML: 122 -
NASAL NK/T- CELL LYMPHOMA. COMPARATIVE ANALYSIS OF A MEXICAN POPULATION
1782PDF: 999HTML: 1790Tables: 182 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1067PDF: 1175Suppl. Files: 570HTML: 90 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
498PDF: 251HTML: 79 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3991Suppl. Files: 1135PDF: 1085Html: 180 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1777PDF: 1178HTML: 252 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2829PDF: 1016HTML: 5526 -
ASSOCIATION BETWEEN PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE INFECTION PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE
178PDF: 240Suppl. Files: 39HTML: 25 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2149PDF: 1330HTML: 3505 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1102PDF: 853HTML: 252 -
CEREBRAL VENOUS THROMBOSIS IN THE MEDITERRANEAN AREA IN CHILDREN
2528PDF: 955HTML: 2241 -
PATHOGENESIS OF MALARIA IN TISSUES AND BLOOD
4547PDF: 1938HTML: 17803 -
CANDIDA ASSOCIATED BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOLOGY PATIENTS: SINGLE CENTER EXPERIENCE
4404PDF: 924HTML: 1329Table1: 185 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2634PDF: 1627HTML: 2373Table1: 193 -
IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma
56PDF: 55HTML: 3 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2920PDF: 1370HTML: 3575Untitled: 195Untitled: 211Untitled: 184 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1470PDF: 887HTML: 318 -
WHAT ARE FUNGAL INFECTIONS?
4235PDF: 2406HTML: 27629de Pauw: 241 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
2051PDF: 812HTML: 1051 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1993PDF: 765HTML: 702 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12396PDF: 1683HTML: 4207Cover letter: 204Figure 1: 212







